Abstract:An increasing number of pathogenic variants in presynaptic proteins involved in the synaptic vesicle cycle are being discovered in neurodevelopmental disorders. The clinical features of these synaptic vesicle cycle disorders are diverse, but the most prevalent phenotypes include intellectual disability, epilepsy, movement disorders, cerebral visual impairment, and psychiatric symptoms (Verhage and Sørensen, 2020; Bonnycastle et al., 2021; John et al., 2021; Melland et al., 2021). Among this growing list of synaptic vesicle cycle disorders, the most frequent is STXBP1 encephalopathy caused by d e novo heterozygous pathogenic variants in syntaxin-binding protein 1 (STXBP1, also known as MUNC18-1) (Verhage and Sørensen, 2020; John et al., 2021). STXBP1 is an essential protein for presynaptic neurotransmitter release. Its haploinsufficiency is the main disease mechanism and impairs both excitatory and inhibitory neurotransmitter release. However, the disease pathogenesis and cellular origins of the broad spectrum of neurological phenotypes are poorly understood. Here we generate cell type-specific Stxbp1 haploinsufficient male and female mice and show that Stxbp1 haploinsufficiency in GABAergic/glycinergic neurons causes developmental delay, epilepsy, motor, cognitive, and psychiatric deficits, recapitulating majority of the phenotypes observed in the constitutive Stxbp1 haploinsufficient mice and STXBP1 encephalopathy. In contrast, Stxbp1 haploinsufficiency in glutamatergic neurons results in a small subset of cognitive and seizure phenotypes distinct from those caused by Stxbp1 haploinsufficiency in GABAergic/glycinergic neurons. Thus, the contrasting roles of excitatory and inhibitory signaling reveal GABAergic/glycinergic dysfunction as a key disease mechanism of STXBP1 encephalopathy and suggest the possibility to selectively modulate disease phenotypes by targeting specific neurotransmitter systems. Significance statement Heterozygous pathogenic variants in STXBP1 are in the top five causes of pediatric epilepsies and one of the most frequent causes of neurodevelopmental disorders. They affect presynaptic neurotransmitter release and a broad spectrum of neurological features common among neurodevelopmental disorders, but the disease pathogenesis and cell types subserving these phenotypes remain unclear. Here we report the distinct roles of GABAergic/glycinergic and glutamatergic neurons in the pathogenesis of STXBP1 encephalopathy. These results will aid the development of therapeutic interventions by suggesting the potential outcomes of therapeutic strategies that target different neuronal types for treating STXBP1 encephalopathy.

SNX8 enables lysosome reformation and reverses lysosomal storage disorder

Small molecule modulator of neuronal lysosome positioning and function resolves Alzheimers Disease-linked pathologies in cultured human neurons

Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders

Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis

Neurodegenerative Lysosomal Storage Disorders: TPC2 Comes to the Rescue!

Lipid-mediated motor-adaptor sequestration impairs axonal lysosome delivery leading to autophagic stress and dystrophy in Niemann-Pick type C

Kansl1 haploinsufficiency impairs autophagosome-lysosome fusion and links autophagic dysfunction with Koolen-de Vries syndrome in mice

Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models

Biallelic loss-of-function variants of SLC12A9 cause lysosome dysfunction and a syndromic neurodevelopmental disorder

Myeloid-derived β-hexosaminidase is essential for neuronal health and lysosome function: implications for Sandhoff disease

Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells

Reversing Lysosome-Ribosome Circuit Dysregulation Mitigates C9FTD/ALS Neurodegeneration and Behaviors

Targeting impaired autophagy as a therapeutic strategy for Koolen-de Vries syndrome

Systemic gene therapy corrects the neurological phenotype in a mouse model of NGLY1 deficiency

A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation

Cell-Type Resolved Protein Atlas of Brain Lysosomes Identifies SLC45A1-Associated Disease as a Lysosomal Disorder

GABAergic/glycinergic and glutamatergic neurons mediate distinct neurodevelopmental phenotypes of STXBP1 encephalopathy

Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification

Lysosomal Dysfunction: Connecting the Dots in the Landscape of Human Diseases

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

The lysosomal trafficking regulator "LYST": an 80-year traffic jam